| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 22, 2017
LEXINGTON, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
-
Sep 14, 2017
LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its...
-
Sep 11, 2017Results from 34 Patients Demonstrate Positive Safety Profile and Support Decision to Expand Development
LEXINGTON, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
-
Sep 6, 2017
LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
-
Aug 31, 2017
LEXINGTON, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...